Immunotherapy, prognostic, and tumor biomarker based on pancancer analysis, SMARCD3.

ABSTRACT:

Background

SMARCD3 has recently been shown to be an important gene affecting cancer, playing an important role in medulloblastoma and pancreatic ductal adenocarcinoma. Therefore, we conducted this research to investigate the potential involvement of SMARCD3 across cancers and to offer recommendations for future studies.

Methods

Utilizing information on 33 malignancies in the UCSC Xena database, SMARCD3 expression and its prognostic value were assessed. The tumor microenvironment was evaluated with the "CIBERSORT" and "ESTIMATE" algorithms. SMARCD3 and immune-related genes were analyzed using the TISIDB website. The pathways related to the target genes were examined using GSEA. MSI (microsatellite instability), TMB (tumor mutational burden), and immunotherapy analysis were us

SUBMITTER: Guo Z 

PROVIDER: S-EPMC11210247 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature